D. Marshall Porterfield

A major requirement for humans is a breathable atmosphere. In microgravity, despite environmental life support systems regulating air exchange, astronauts complain about air quality, with elevated CO2-levels resulting in detrimental health and performance effects. We extend extant accounts of human respiration to include the role of gravity and buoyancy. Using computational fluid dynamics, we demonstrate that the absence of biothermal convection in microgravity reduces airflow around the human body. This impairs gas exchange by creating an environmental breathing deadspace in front of the face, leading to significant CO2-rebreathing, with implications for astronaut health and countermeasures. In 1g, increasing ambient air temperature can also reduce efficient respiratory exchange, resulting in breathing conditions equivalent to those in microgravity, with implications for treating respiratory disease on Earth.

Funding organizations around the world are adopting open science policies, resulting in a pressing need for open science programs. In response to the 2011 decadal survey, NASA sought to expand and accelerate omics research, releasing its GeneLab Strategic Plan in 2014. GeneLab is an open science data repository and analysis portal for spaceflight and space-relevant omics data. GeneLab’s output has been outstanding, but its full potential as a way to transform space biology has not yet been achieved. NASA should pursue the development of GeneLab as an open science platorm in earnest.

NASA and the CNSA have both released plans for lunar human exploration. This paper reviews those plans through the lens of strategic capability development. It examines the history of NASA’s development of bioregenerative space habitation systems and shows how past research and policy decisions, including funding cuts and program discontinuations, have led to critical gaps in current NASA capabilities. These gaps pose a strategic risk to US leadership in human space exploration that must be addressed urgently to sustain international competitiveness. It concludes with recommendations for program investments crucial for the deployment of mature bioregenerative technologies in the coming decade.